Research Use Only · Dosing data compiled from published literature · Not for human or veterinary use

Tesamorelin Dosage & Reconstitution

TH9507, Egrifta. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: clinical.

1Set Up Your Mix

5 mg/mL · 5000 mcg/mL

Your Answer — Tesamorelin

10 mg in 2 mL
20Draw To This Line
0.2That's This Many mL
10Doses In The Vial
0102030405060708090100 U-100 syringe · 1 mL · 100 units draw to 20
10 mg ÷ 2 mL = 5 mg/mL  →  1 mg ÷ 5 mg/mL = 0.2 mL  →  × 100 = 20 units
Looks good. Draw to 20 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 10 doses.
When to dose
Time of dayBefore bed, or first thing in the morning — not during the day.
FoodFasted. Nothing to eat for about 2 hours before, and wait 20–30 minutes after.

Food, and carbohydrate in particular, raises insulin and blunts the growth-hormone pulse these compounds are meant to trigger. The two windows where you are naturally fasted and GH release is highest are early sleep and first thing on waking, which is why those are the only two sensible times.

2Week-By-Week Plan — Tesamorelin

Start low, work up
WhenDoseHow OftenHow Many mLDraw ToNumber Of DosesPeptide Used
Weeks 1–2 1 mg daily 0.2 mL 20 u 14 14 mg
Week 3 onward
per 4 weeks from here on
2 mg daily 0.4 mL 40 u 28 56 mg
Time until the top dose
2 weeks
Peptide used getting there
14 mg
Vials you'll need
2 × 10 mg
Once you're at the top dose
56 mg / 4 wk · 5.6 vials
Where this plan came from
Built from this peptide's dose range
Where this came from: Built from the doses listed for this peptide below — start at the lowest and step up, using the studies cited on this page. Nobody publishes a week-by-week plan for this peptide, so we built one: the doses are the researched ones shown below, and we simply put them in order from lowest to highest. Treat it as a starting point, not an official schedule.

3Common Doses — Tesamorelin

worked out for your mix
LevelDoseHow OftenHow Many mLDraw ToDoses In Vial
Label dose 2 mg 1× daily 0.4 mL 40 u 5 doses
Lower reported 1 mg 1× daily 0.2 mL 20 u 10 doses
Trial arm 2 mg daily, 26–52 wk 0.4 mL 40 u 5 doses
Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About Tesamorelin

GH Secretagogue
Also known as
TH9507, Egrifta
Class
GH Secretagogue
Route
Subcutaneous
Half-life
~26–38 min
Evidence tier
Clinical

An FDA-approved GHRH analogue for HIV-associated lipodystrophy — the only compound in this class with a full approval and a defined label dose. Two large phase 3 trials support the 2 mg daily figure.

Buy Tesamorelin

Common Questions — Tesamorelin

How much bacteriostatic water do I add to a 10 mg vial of Tesamorelin?

Adding 2 mL of bacteriostatic water to a 10 mg vial gives 5 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.

What dose of Tesamorelin is used in research?

Published and reported figures for Tesamorelin run from 1 mg to 2 mg, typically 1× daily. This site lists each figure with the source it came from rather than giving a single recommended number.

How many units on the syringe is a 2 mg dose of Tesamorelin?

At 5 mg/mL, a 2 mg dose is 40 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 5 doses.

How strong is the evidence behind these Tesamorelin doses?

Tesamorelin is graded clinical. Human trial or approved-label dosing has been published for this compound. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.

Where These Numbers Come From

Clinical — Human trial or approved-label dosing published
Effects of tesamorelin on visceral fat in HIV-associated lipodystrophy Falutz J, et al. New England Journal of Medicine, 2007
The pivotal phase 3 trial establishing 2 mg daily.
Find on PubMed ↗
Long-term safety and effects of tesamorelin — 52-week extension Falutz J, et al. AIDS, 2010
Extended safety and durability data at the same dose.
Find on PubMed ↗
Effects of tesamorelin on liver fat and cognition Stanley TL, et al. The Lancet HIV / JAMA, 2019
Later trials extending the indication evidence beyond visceral fat.
Find on PubMed ↗

Newest Studies —

Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

Other gh secretagogue peptides

Compounds in the same class, or browse the full catalogue.

CJC-1295 (no DAC)

A tetra-substituted GHRH(1-29) analogue without the drug affinity complex, giving a short pulse rather than sustained elevation. F…

CJC-1295 DAC

GHRH analogue conjugated to bind serum albumin, extending half-life from minutes to days. This produces sustained GH/IGF-1 elevati…

All 72 peptides

Every compound compared in one table: dose range, how often, half-life and evidence tier.

Need this on one page to print, screenshot or send?

Make a dose card →